Key result
Platelets from hypertensive individuals had significantly higher PMCA tyrosine phosphorylation compared to normotensive subjects (1.82 vs 0.53; P<0.0005).
Why the study?
Is tyrosine phosphorylation of platelet PMCA increased in untreated hypertensive patients compared to normotensive individuals?
Population
23 volunteers (15 normotensive, 8 untreated hypertensive)
Comparison
Untreated hypertension vs Normotension
Design
Case-control
Authors
Loading...
Hypothesis-generating for PMCA in hypertension; prospective studies needed before clinical relevance.
Case-Control (n=23)
Is tyrosine phosphorylation of platelet PMCA increased in untreated hypertensive patients compared to normotensive individuals?
Absolute Event Rate: 1.82% vs 0.53%
p-value: p=<0.0005
Tyrosine phosphorylation of PMCA is increased in platelets of hypertensive individuals, which may explain the inhibition of the Ca2+ pump and subsequent platelet hyperactivity.
Blankenship et al. (2000) conducted a case-control in Hypertension (n=23). Hypertension vs. Normotensive status was evaluated on PMCA tyrosine phosphorylation (normalized phosphotyrosine chemiluminescence per nanogram PMCA) (p=<0.0005). Platelets from hypertensive individuals had significantly higher PMCA tyrosine phosphorylation compared to normotensive subjects (1.82 vs 0.53; P<0.0005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: